ACCURAY INCORPORATED (NASDAQ:ARAY) Files An 8-K Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition.

On January10, 2017, Accuray Incorporated (Accuray or the Company)
announced certain preliminary estimated financial results for the
Company for the quarter ended December31, 2016. This information
is contained in the management presentation attached hereto as
Exhibit99.1.

Highlights for the second fiscal quarter of 2017 include:

Gross orders expected to be approximately $78 million

Age-outs of approximately $20 million

Cancellations of approximately $4 million

Total revenue expected to be approximately $87 million

The above information is preliminary and subject to completion of
quarter-end financial reporting processes and review.

Accuray plans to reports its full second quarter results during
the week of January30th.

Safe Harbor

Statements in this release concerning Accurays financial
operating results for the quarter ended December31, 2016 are
forward-looking statements that involve a number of uncertainties
and risks. Actual results could differ materially from those
anticipated in the forward-looking statements as a result of
certain factors, including: potential differences between
Accurays preliminary analysis and the final results for the
quarter ended December31, 2016 as a result of the completion of
financial reporting processes and review, and other factors
listed in Accurays annual report made on Form10-K for the fiscal
year ended June30, 2016, in particular under the heading Risk
Factors as filed with the Securities and Exchange Commission as
well as Accurays other filings with the Securities and Exchange
Commission. All statements made in this Form8-K and Exhibit99.1
are made only as of the date hereof. Accuray undertakes no
obligation to update the information in this release in the event
facts or circumstances subsequently change after the date of this
filing.

Item 7.01. Regulation FD Disclosure

Representatives of the Company intend to present the management
presentation slides, attached hereto as Exhibit99.1, in
presentations during a conference from January10 11, 2017, and
may make use of the slides in additional presentations to
investors and analysts from time to time. The presentation slides
will also be posted on the investor relations portion of the
Companys website.

The foregoing information (including the exhibit hereto) is being
furnished under Item2.02 Results of Operations and Financial
Condition and Item 7.01 Regulation FD Disclosure and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), nor shall it be
deemed incorporated by reference in any filing under the
Securities Act of 1933, as amended, or the Exchange Act except as
shall be expressly set forth by specific reference in such
filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

About ACCURAY INCORPORATED (NASDAQ:ARAY)

Accuray Incorporated is a radiation oncology company. The Company develops, manufactures and markets medical devices used in radiation therapy for the treatment of cancer patients. Its products include the CyberKnife Systems, the TomoTherapy Systems, and the Radixact Delivery Treatment Platform. Its technologies, the CyberKnife and TomoTherapy Systems, are designed to deliver treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image guided radiation therapy (IGRT) and adaptive radiation therapy. The CyberKnife Systems are robotic systems that are used to treat various types of cancer and tumors throughout the body. The CyberKnife Systems track, detect and correct for tumor and patient movement in real-time during the procedure. The TomoTherapy Systems include the TomoTherapy H Series with configuration options of TomoH, TomoHD and TomoHDA.

ACCURAY INCORPORATED (NASDAQ:ARAY) Recent Trading Information

ACCURAY INCORPORATED (NASDAQ:ARAY) closed its last trading session up +0.05 at 5.05 with 924,958 shares trading hands.